schliessen

Filtern

 

Bibliotheken

Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats

Aims/hypothesis High plasma copeptin, a marker of vasopressin (VP) secretion, has been shown to be associated with the metabolic syndrome and development of type 2 diabetes in humans. The present study was designed to determine the long-term influence of plasma VP concentration in a rodent model pro... Full description

Journal Title: Diabetologia 2015-01-27, Vol.58 (5), p.1081-1090
Main Author: Taveau, Christopher
Other Authors: Chollet, Catherine , Waeckel, Ludovic , Desposito, Dorinne , Bichet, Daniel G , Arthus, Marie-Françoise , Magnan, Christophe , Philippe, Erwann , Paradis, Valerie , Foufelle, Fabienne , Hainault, Isabelle , Enhorning, Sofia , Velho, Gilberto , Roussel, Ronan , Bankir, Lise , Melander, Olle , Bouby, Nadine
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 0012-186X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_lup_lub_lu_se_82fd37a6_41cd_4f27_bd55_cd057c7522d7
title: Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats
format: Article
creator:
  • Taveau, Christopher
  • Chollet, Catherine
  • Waeckel, Ludovic
  • Desposito, Dorinne
  • Bichet, Daniel G
  • Arthus, Marie-Françoise
  • Magnan, Christophe
  • Philippe, Erwann
  • Paradis, Valerie
  • Foufelle, Fabienne
  • Hainault, Isabelle
  • Enhorning, Sofia
  • Velho, Gilberto
  • Roussel, Ronan
  • Bankir, Lise
  • Melander, Olle
  • Bouby, Nadine
subjects:
  • Animals
  • Antidiuretic Hormone Receptor Antagonists - pharmacology
  • Article
  • Blood Glucose - metabolism
  • Clinical Medicine
  • Dextrose
  • Drinking - physiology
  • Endocrinology and Diabetes
  • Endokrinologi och diabetes
  • Fatty Liver - etiology
  • Fatty Liver - metabolism
  • Glucose
  • Glucose intolerance
  • Glucose Intolerance - etiology
  • Glucose Intolerance - metabolism
  • Glucose Tolerance Test
  • Glucosemetabolism
  • Human Physiology
  • Hydration
  • Indoles - pharmacology
  • Internal Medicine
  • Klinisk medicin
  • Lipid metabolism
  • Liver
  • Male
  • Medical and Health Sciences
  • Medicin och hälsovetenskap
  • Medicine
  • Medicine & Public Health
  • Metabolic Diseases
  • Obesity
  • Obesity - metabolism
  • Physiological aspects
  • Pyrrolidines - pharmacology
  • Rats, Zucker
  • Triglycerides
  • Type 2 diabetes
  • Vasopressin
  • Vasopressins - blood
  • Vasopressins - pharmacology
ispartof: Diabetologia, 2015-01-27, Vol.58 (5), p.1081-1090
description: Aims/hypothesis High plasma copeptin, a marker of vasopressin (VP) secretion, has been shown to be associated with the metabolic syndrome and development of type 2 diabetes in humans. The present study was designed to determine the long-term influence of plasma VP concentration in a rodent model prone to metabolic dysfunction. Methods Obese Zucker rats and their lean counterparts were submitted for 4 weeks to one of three protocols inducing different levels of VP. Circulating VP was either reduced by increasing the daily water intake (low-VP), or increased by a chronic i.p. infusion of VP (high-VP). The control rats had normal VP levels that depended on their own regulation of water intake and VP secretion. Results Compared with controls with normal VP, lean rats with high-VP had a higher fasting glycaemia after 4 weeks. In obese rats, high-VP promoted hyperinsulinaemia, glucose intolerance, assessed by glucose and insulin tolerance tests, and an impaired response to a pyruvate challenge. Conversely, treatment with a selective arginine vasopressin receptor 1A (V1aR) antagonist reduced glucose intolerance. Low-VP obese rats had unchanged glucose tolerance but exhibited a drastic decrease in liver steatosis compared with control obese rats, associated with low hepatic triacylglycerol and cholesterol content, and reduced expression of hepatic lipogenic genes. These effects were independent of changes in body adiposity, and plasma sodium and osmolality did not differ among groups. Conclusion/interpretation These findings show a causal relationship between the VP–hydration axis and the metabolic risk. Therapeutic perspectives include diet recommendations regarding hydration, but also potential pharmacological interventions targeting the VP V1aR.
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6406524
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_lup_lub_lu_se_82fd37a6_41cd_4f27_bd55_cd057c7522d7
sourceformatXML
sourcesystemPC
galeidA409072944
sourcerecordidA409072944
originalsourceidFETCH-LOGICAL-1556t-e15d5af79957cdf50f1e9f0f5ed86bc7d9ae230845398f51b422823787a5ea210
addsrcrecordideNp9klGP1CAUhRujccfVH-CLIfHFl65AoZTHzUZXk0l8UeMboXCZZUJLhVYz_166M666UUMICXzncC-cqnpO8AXBWLzOGBPKa0x43TDZ1vJBtSGsoTVmtHtYbdbjmnTtl7PqSc57jHHDWfu4OqO8pbRr6aY6fNY5Tgly9iPSo0U3B5v07OOIpqAPSKNB72NCKQZABZlvAFn4BiFOA4wzig7twmJiXk_nAiU9Gjg6wVSMDMoz6Dlmn1d97KGg5Yb8tHrkdMjw7LSeV5_evvl49a7efrh-f3W5rQnn7VwD4ZZrJ6TkwljHsSMgHXYcbNf2RlipgTa4Y7yRneOkZ6Uz2ohOaA6aEnxebY---TtMS6-m5AedDipqr8IyldmXqTKojjrbCN0qRoxVzFGhesu5MhaXuwWn1Ipi9-poN6X4dYE8q8FnAyHoEeKSFWkFbbFoGlrQl_fQfVzSWJpdKSI71lH5i9rpAMqPLs5Jm9VUXTIssaCSsUJd_IUqw8LgTRzB-bL_h4AcBSbFnBO4u8YJVmt61DE9qqRHrelRaykvTgUv_QD2TvEzLgUQ90yNn2_TUqrx4b_W9PQLxXTcQfrtLf4p-gExvd_2
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1671984829
display
typearticle
titleVasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats
creatorTaveau, Christopher ; Chollet, Catherine ; Waeckel, Ludovic ; Desposito, Dorinne ; Bichet, Daniel G ; Arthus, Marie-Françoise ; Magnan, Christophe ; Philippe, Erwann ; Paradis, Valerie ; Foufelle, Fabienne ; Hainault, Isabelle ; Enhorning, Sofia ; Velho, Gilberto ; Roussel, Ronan ; Bankir, Lise ; Melander, Olle ; Bouby, Nadine
creatorcontribTaveau, Christopher ; Chollet, Catherine ; Waeckel, Ludovic ; Desposito, Dorinne ; Bichet, Daniel G ; Arthus, Marie-Françoise ; Magnan, Christophe ; Philippe, Erwann ; Paradis, Valerie ; Foufelle, Fabienne ; Hainault, Isabelle ; Enhorning, Sofia ; Velho, Gilberto ; Roussel, Ronan ; Bankir, Lise ; Melander, Olle ; Bouby, Nadine
descriptionAims/hypothesis High plasma copeptin, a marker of vasopressin (VP) secretion, has been shown to be associated with the metabolic syndrome and development of type 2 diabetes in humans. The present study was designed to determine the long-term influence of plasma VP concentration in a rodent model prone to metabolic dysfunction. Methods Obese Zucker rats and their lean counterparts were submitted for 4 weeks to one of three protocols inducing different levels of VP. Circulating VP was either reduced by increasing the daily water intake (low-VP), or increased by a chronic i.p. infusion of VP (high-VP). The control rats had normal VP levels that depended on their own regulation of water intake and VP secretion. Results Compared with controls with normal VP, lean rats with high-VP had a higher fasting glycaemia after 4 weeks. In obese rats, high-VP promoted hyperinsulinaemia, glucose intolerance, assessed by glucose and insulin tolerance tests, and an impaired response to a pyruvate challenge. Conversely, treatment with a selective arginine vasopressin receptor 1A (V1aR) antagonist reduced glucose intolerance. Low-VP obese rats had unchanged glucose tolerance but exhibited a drastic decrease in liver steatosis compared with control obese rats, associated with low hepatic triacylglycerol and cholesterol content, and reduced expression of hepatic lipogenic genes. These effects were independent of changes in body adiposity, and plasma sodium and osmolality did not differ among groups. Conclusion/interpretation These findings show a causal relationship between the VP–hydration axis and the metabolic risk. Therapeutic perspectives include diet recommendations regarding hydration, but also potential pharmacological interventions targeting the VP V1aR.
identifier
0ISSN: 0012-186X
1ISSN: 1432-0428
2EISSN: 1432-0428
3DOI: 10.1007/s00125-015-3496-9
4PMID: 25622862
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subjectAnimals ; Antidiuretic Hormone Receptor Antagonists - pharmacology ; Article ; Blood Glucose - metabolism ; Clinical Medicine ; Dextrose ; Drinking - physiology ; Endocrinology and Diabetes ; Endokrinologi och diabetes ; Fatty Liver - etiology ; Fatty Liver - metabolism ; Glucose ; Glucose intolerance ; Glucose Intolerance - etiology ; Glucose Intolerance - metabolism ; Glucose Tolerance Test ; Glucosemetabolism ; Human Physiology ; Hydration ; Indoles - pharmacology ; Internal Medicine ; Klinisk medicin ; Lipid metabolism ; Liver ; Male ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Obesity ; Obesity - metabolism ; Physiological aspects ; Pyrrolidines - pharmacology ; Rats, Zucker ; Triglycerides ; Type 2 diabetes ; Vasopressin ; Vasopressins - blood ; Vasopressins - pharmacology
ispartofDiabetologia, 2015-01-27, Vol.58 (5), p.1081-1090
rights
0Springer-Verlag Berlin Heidelberg 2015
1COPYRIGHT 2015 Springer
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1556t-e15d5af79957cdf50f1e9f0f5ed86bc7d9ae230845398f51b422823787a5ea210
citesFETCH-LOGICAL-1556t-e15d5af79957cdf50f1e9f0f5ed86bc7d9ae230845398f51b422823787a5ea210
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25622862$$D View this record in MEDLINE/PubMed
1$$Uhttps://lup.lub.lu.se/record/5386061$$DView record from Swedish Publication Index
search
creatorcontrib
0Taveau, Christopher
1Chollet, Catherine
2Waeckel, Ludovic
3Desposito, Dorinne
4Bichet, Daniel G
5Arthus, Marie-Françoise
6Magnan, Christophe
7Philippe, Erwann
8Paradis, Valerie
9Foufelle, Fabienne
10Hainault, Isabelle
11Enhorning, Sofia
12Velho, Gilberto
13Roussel, Ronan
14Bankir, Lise
15Melander, Olle
16Bouby, Nadine
title
0Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats
1Diabetologia
addtitle
0Diabetologia
1Diabetologia
descriptionAims/hypothesis High plasma copeptin, a marker of vasopressin (VP) secretion, has been shown to be associated with the metabolic syndrome and development of type 2 diabetes in humans. The present study was designed to determine the long-term influence of plasma VP concentration in a rodent model prone to metabolic dysfunction. Methods Obese Zucker rats and their lean counterparts were submitted for 4 weeks to one of three protocols inducing different levels of VP. Circulating VP was either reduced by increasing the daily water intake (low-VP), or increased by a chronic i.p. infusion of VP (high-VP). The control rats had normal VP levels that depended on their own regulation of water intake and VP secretion. Results Compared with controls with normal VP, lean rats with high-VP had a higher fasting glycaemia after 4 weeks. In obese rats, high-VP promoted hyperinsulinaemia, glucose intolerance, assessed by glucose and insulin tolerance tests, and an impaired response to a pyruvate challenge. Conversely, treatment with a selective arginine vasopressin receptor 1A (V1aR) antagonist reduced glucose intolerance. Low-VP obese rats had unchanged glucose tolerance but exhibited a drastic decrease in liver steatosis compared with control obese rats, associated with low hepatic triacylglycerol and cholesterol content, and reduced expression of hepatic lipogenic genes. These effects were independent of changes in body adiposity, and plasma sodium and osmolality did not differ among groups. Conclusion/interpretation These findings show a causal relationship between the VP–hydration axis and the metabolic risk. Therapeutic perspectives include diet recommendations regarding hydration, but also potential pharmacological interventions targeting the VP V1aR.
subject
0Animals
1Antidiuretic Hormone Receptor Antagonists - pharmacology
2Article
3Blood Glucose - metabolism
4Clinical Medicine
5Dextrose
6Drinking - physiology
7Endocrinology and Diabetes
8Endokrinologi och diabetes
9Fatty Liver - etiology
10Fatty Liver - metabolism
11Glucose
12Glucose intolerance
13Glucose Intolerance - etiology
14Glucose Intolerance - metabolism
15Glucose Tolerance Test
16Glucosemetabolism
17Human Physiology
18Hydration
19Indoles - pharmacology
20Internal Medicine
21Klinisk medicin
22Lipid metabolism
23Liver
24Male
25Medical and Health Sciences
26Medicin och hälsovetenskap
27Medicine
28Medicine & Public Health
29Metabolic Diseases
30Obesity
31Obesity - metabolism
32Physiological aspects
33Pyrrolidines - pharmacology
34Rats, Zucker
35Triglycerides
36Type 2 diabetes
37Vasopressin
38Vasopressins - blood
39Vasopressins - pharmacology
issn
00012-186X
11432-0428
21432-0428
fulltextfalse
rsrctypearticle
creationdate2015
recordtypearticle
recordideNp9klGP1CAUhRujccfVH-CLIfHFl65AoZTHzUZXk0l8UeMboXCZZUJLhVYz_166M666UUMICXzncC-cqnpO8AXBWLzOGBPKa0x43TDZ1vJBtSGsoTVmtHtYbdbjmnTtl7PqSc57jHHDWfu4OqO8pbRr6aY6fNY5Tgly9iPSo0U3B5v07OOIpqAPSKNB72NCKQZABZlvAFn4BiFOA4wzig7twmJiXk_nAiU9Gjg6wVSMDMoz6Dlmn1d97KGg5Yb8tHrkdMjw7LSeV5_evvl49a7efrh-f3W5rQnn7VwD4ZZrJ6TkwljHsSMgHXYcbNf2RlipgTa4Y7yRneOkZ6Uz2ohOaA6aEnxebY---TtMS6-m5AedDipqr8IyldmXqTKojjrbCN0qRoxVzFGhesu5MhaXuwWn1Ipi9-poN6X4dYE8q8FnAyHoEeKSFWkFbbFoGlrQl_fQfVzSWJpdKSI71lH5i9rpAMqPLs5Jm9VUXTIssaCSsUJd_IUqw8LgTRzB-bL_h4AcBSbFnBO4u8YJVmt61DE9qqRHrelRaykvTgUv_QD2TvEzLgUQ90yNn2_TUqrx4b_W9PQLxXTcQfrtLf4p-gExvd_2
startdate20150127
enddate20150127
creator
0Taveau, Christopher
1Chollet, Catherine
2Waeckel, Ludovic
3Desposito, Dorinne
4Bichet, Daniel G
5Arthus, Marie-Françoise
6Magnan, Christophe
7Philippe, Erwann
8Paradis, Valerie
9Foufelle, Fabienne
10Hainault, Isabelle
11Enhorning, Sofia
12Velho, Gilberto
13Roussel, Ronan
14Bankir, Lise
15Melander, Olle
16Bouby, Nadine
general
0Springer Berlin Heidelberg
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107T5
117X7
127XB
1388E
148AO
158C1
168FI
178FJ
188FK
19ABUWG
20BENPR
21FYUFA
22GHDGH
23H94
24K9.
25M0S
26M1P
27PQEST
28PQQKQ
29PQUKI
30PRINS
317X8
32ADTPV
33AOWAS
34D95
sort
creationdate20150127
titleVasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats
authorTaveau, Christopher ; Chollet, Catherine ; Waeckel, Ludovic ; Desposito, Dorinne ; Bichet, Daniel G ; Arthus, Marie-Françoise ; Magnan, Christophe ; Philippe, Erwann ; Paradis, Valerie ; Foufelle, Fabienne ; Hainault, Isabelle ; Enhorning, Sofia ; Velho, Gilberto ; Roussel, Ronan ; Bankir, Lise ; Melander, Olle ; Bouby, Nadine
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1556t-e15d5af79957cdf50f1e9f0f5ed86bc7d9ae230845398f51b422823787a5ea210
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Animals
1Antidiuretic Hormone Receptor Antagonists - pharmacology
2Article
3Blood Glucose - metabolism
4Clinical Medicine
5Dextrose
6Drinking - physiology
7Endocrinology and Diabetes
8Endokrinologi och diabetes
9Fatty Liver - etiology
10Fatty Liver - metabolism
11Glucose
12Glucose intolerance
13Glucose Intolerance - etiology
14Glucose Intolerance - metabolism
15Glucose Tolerance Test
16Glucosemetabolism
17Human Physiology
18Hydration
19Indoles - pharmacology
20Internal Medicine
21Klinisk medicin
22Lipid metabolism
23Liver
24Male
25Medical and Health Sciences
26Medicin och hälsovetenskap
27Medicine
28Medicine & Public Health
29Metabolic Diseases
30Obesity
31Obesity - metabolism
32Physiological aspects
33Pyrrolidines - pharmacology
34Rats, Zucker
35Triglycerides
36Type 2 diabetes
37Vasopressin
38Vasopressins - blood
39Vasopressins - pharmacology
toplevelpeer_reviewed
creatorcontrib
0Taveau, Christopher
1Chollet, Catherine
2Waeckel, Ludovic
3Desposito, Dorinne
4Bichet, Daniel G
5Arthus, Marie-Françoise
6Magnan, Christophe
7Philippe, Erwann
8Paradis, Valerie
9Foufelle, Fabienne
10Hainault, Isabelle
11Enhorning, Sofia
12Velho, Gilberto
13Roussel, Ronan
14Bankir, Lise
15Melander, Olle
16Bouby, Nadine
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Immunology Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13ProQuest Pharma Collection
14Public Health Database
15Hospital Premium Collection
16Hospital Premium Collection (Alumni Edition)
17ProQuest Central (Alumni) (purchase pre-March 2016)
18ProQuest Central (Alumni Edition)
19ProQuest Central
20Health Research Premium Collection
21Health Research Premium Collection (Alumni)
22AIDS and Cancer Research Abstracts
23ProQuest Health & Medical Complete (Alumni)
24Health & Medical Collection (Alumni Edition)
25Medical Database
26ProQuest One Academic Eastern Edition
27ProQuest One Academic
28ProQuest One Academic UKI Edition
29ProQuest Central China
30MEDLINE - Academic
31SwePub
32SwePub Articles
33SWEPUB Lunds universitet
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Taveau, Christopher
1Chollet, Catherine
2Waeckel, Ludovic
3Desposito, Dorinne
4Bichet, Daniel G
5Arthus, Marie-Françoise
6Magnan, Christophe
7Philippe, Erwann
8Paradis, Valerie
9Foufelle, Fabienne
10Hainault, Isabelle
11Enhorning, Sofia
12Velho, Gilberto
13Roussel, Ronan
14Bankir, Lise
15Melander, Olle
16Bouby, Nadine
formatjournal
genrearticle
ristypeJOUR
atitleVasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats
jtitleDiabetologia
stitleDiabetologia
addtitleDiabetologia
date2015-01-27
risdate2015
volume58
issue5
spage1081
epage1090
pages1081-1090
issn
00012-186X
11432-0428
eissn1432-0428
abstractAims/hypothesis High plasma copeptin, a marker of vasopressin (VP) secretion, has been shown to be associated with the metabolic syndrome and development of type 2 diabetes in humans. The present study was designed to determine the long-term influence of plasma VP concentration in a rodent model prone to metabolic dysfunction. Methods Obese Zucker rats and their lean counterparts were submitted for 4 weeks to one of three protocols inducing different levels of VP. Circulating VP was either reduced by increasing the daily water intake (low-VP), or increased by a chronic i.p. infusion of VP (high-VP). The control rats had normal VP levels that depended on their own regulation of water intake and VP secretion. Results Compared with controls with normal VP, lean rats with high-VP had a higher fasting glycaemia after 4 weeks. In obese rats, high-VP promoted hyperinsulinaemia, glucose intolerance, assessed by glucose and insulin tolerance tests, and an impaired response to a pyruvate challenge. Conversely, treatment with a selective arginine vasopressin receptor 1A (V1aR) antagonist reduced glucose intolerance. Low-VP obese rats had unchanged glucose tolerance but exhibited a drastic decrease in liver steatosis compared with control obese rats, associated with low hepatic triacylglycerol and cholesterol content, and reduced expression of hepatic lipogenic genes. These effects were independent of changes in body adiposity, and plasma sodium and osmolality did not differ among groups. Conclusion/interpretation These findings show a causal relationship between the VP–hydration axis and the metabolic risk. Therapeutic perspectives include diet recommendations regarding hydration, but also potential pharmacological interventions targeting the VP V1aR.
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid25622862
doi10.1007/s00125-015-3496-9
oafree_for_read